WASHINGTON, DC – Congresswoman Carolyn B. Maloney (D-NY), sponsor of H.R. 1980, the Smithsonian Women’s History Museum Act, was joined by original cosponsors Representatives Brian Fitzpatrick (R-PA), Brenda L. Lawrence (D-MI), and Eleanor Holmes Norton (D-DC) in celebrating the bill’s inclusion in the omnibus package announced today.
WASHINGTON, DC – Congresswoman Carolyn B. Maloney (NY-12) today reintroduced The Obstetric Fistula Prevention, Treatment, Hope and Dignity Restoration Act, legislation that would assist the estimated two million women worldwide suffering from obstetric fistula.
WASHINGTON, DC – Congresswoman Carolyn B. Maloney (D-NY) this week wrote to President Paul Kagame of the Republic of Rwanda requesting the immediate release and safe return of Paul Rusesabagina, known for hiding and saving 1,268 refugees as a hotel manager during the 1994 Rwandan genocide. The Congresswoman urged the Rwandan President to return Mr.
NEW YORK, NY - Today, Congresswoman Carolyn B.
WASHINGTON, DC — At today’s Oversight and Reform Subcommittee on Government Operations hearing examining the ongoing presidential transition, its challenges, and lessons already learned that can improve future transitions, Congresswoman Carolyn B.
WASHINGTON, DC — At today’s Oversight and Reform Subcommittee on Civil Rights and Civil Liberties hearing examining the Federal Energy Regulatory Commission’s (FERC) failure to protect the rights of landowners, Congresswoman Carolyn B.
WASHINGTON, DC – Congresswoman Carolyn B. Maloney (D-NY) released the following statement ahead of today’s vote on the Conference Report to H.R. 6395, the William M. (Mac) Thornberry National Defense Authorization Act for FY 2021.
WASHINGTON, DC – Congresswoman Carolyn B. Maloney (D-NY), author of the Corporate Transparency Act, was joined by the FACT Coalition today to applaud the bill’s inclusion in a must pass bill that is expected on the House floor this coming week.
“Yesterday, our country lost an iconic legislator and leader. Senator Paul Sarbanes dedicated his career to bettering the lives of all Marylanders and Americans with his remarkable vision and consistent message of unity. I and so many others are lucky to have called Sen.
Members of the Sackler family and Purdue Pharma's CEO say they did nothing wrong during the years their company illegally marketed Oxycontin and other opioids.
Two key House panels on Thursday announced a joint investigation into the massive cyberattack that has impacted multiple federal agencies, in what may be one of the most damaging digital intrusions in years.
In a surprise development, two members of the Sackler family who served on Purdue Pharma's board until 2018 are testifying Thursday morning under oath before the House Committee on Oversight and Reform.
Their privately owned company developed and aggressively marketed Oxycontin in the 1990s, growing into one of the nation's most profitable opioid producers.
Members of the family who own OxyContin maker Purdue Pharma are scheduled to make a rare appearance Thursday in a public forum, answering questions from a congressional panel about their role in the nation’s long-running opioid addiction crisis.
Aida Corporan has avoided the coronavirus by hunkering down in her apartment at the Bailey Houses, a public housing complex in the Bronx.
But she cannot get away from the health threat inside her own home: mold.
Clark Gascoigne’s entire career has been about ending anonymous shell companies.
Starting at Global Financial Integrity in 2009 and then at the Financial Accountability and Corporate Transparency Coalition, Gascoigne has been on a mission to inject transparency into the ocean of anonymously owned corporate entities that can hide all manner of financial malfeasance.
(AP) -- Two members of the Sackler family who own OxyContin maker Purdue Pharma agreed to appear this week before a congressional committee investigating the family and the company's role in the national opioid addiction and overdose epidemic.
Two Sackler family members who previously served on OxyContin maker Purdue Pharma LP’s board have agreed under pressure to testify this week before a U.S. House of Representatives panel examining the nationwide opioid epidemic, avoiding subpoenas threatened by the committee’s chairwoman.